Remove Drug Trials Remove Research Remove Trials
article thumbnail

Clinical research is about trial and error

pharmaphorum

Clinical research involves trial and error as part of the drug development process. Learn more about how to optimise drug trials and the important role of participants in clinical research.

article thumbnail

Nxera and Cancer Research UK to present promising cancer drug trial at ESMO

Pharma Times

Innovative immunotherapy drug HTL0039732 shows potential in trials

Trials 136
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New drug trial to investigate treatment for patients with bronchiectasis

Pharma Times

200,000 people in the UK have what is considered a ‘hidden’ lung condition

article thumbnail

Unlocking the potential in rare disease research with decentralised trials

pharmaphorum

A survey by rare disease patient network Raremark found that 86% of the community members asked were interested in taking part in clinical trials. CEO Jeremy Edwards looks at how decentralised trial models can solve some of the challenges for clinical trial recruitment in rare disease.

Trials 133
article thumbnail

Beckley adds digital element to its psychedelic drug trials

pharmaphorum

Phase 2 trials of Beckley Psytech’s psychedelic drug candidates will make use of digital technologies for patient monitoring, thanks to a new partnership with Empatica. The post Beckley adds digital element to its psychedelic drug trials appeared first on.

article thumbnail

GSK suffers another R&D setback, axing ulcerative colitis drug trial

pharmaphorum

GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with ulcerative colitis, following a major disappointment with a key lung cancer drug last week. The post GSK suffers another R&D setback, axing ulcerative colitis drug trial appeared first on.

article thumbnail

STAT+: Pfizer scraps half of participants in Lyme disease drug trial due to quality issues

STAT News

Pfizer and partner Valneva are scrapping data from roughly half of the participants in a Phase 3 trial of a Lyme disease vaccine candidate after uncovering quality issues with a third-party clinical trial operator. Continue to STAT+ to read the full story…

Trials 119